Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.

Neuro-oncology（2023）

引用 5|浏览50

暂无评分

摘要

Although the study did not meet predetermined efficacy end point, single-agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients.

查看译文

关键词

Aurora kinase A,alisertib,alisertib pharmacokinetics,atypical teratoid/rhabdoid tumor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要